|
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Experiments were conducted in vivo using systemic administration of Adv-AFP-E1AdB and we observed tumor size reduction in nude mice having liver cancer.
|
11401492 |
2001 |
|
Adult Liver Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this study, we evaluated the liver cancer-specific oncolytic potential of E1B 55kDa-deleted recombinant adenovirus (YKL-1001), which retained other E1 genes driven by the AFP promoter.
|
11911966 |
2002 |
|
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The serum AFP elevation by the infection of HBV and HCV is one of mechanisms which lead to hepatocarcinogenesis, and the antivirus intervening treatment of hepatitis is significant for the prognosis of liver cancer.
|
17465484 |
2007 |
|
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data support the idea that ZHX2 contributes to AFP repression in the liver after birth and may also be involved in AFP reactivation in liver cancer.
|
18194454 |
2008 |
|
Adult Liver Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To address this hypothesis, we carried out global mRNA expression analysis of 21 liver cancer cell lines that produce varying levels of AFP.
|
19038010 |
2008 |
|
Adult Liver Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Cancer targeting gene-viro-therapy specific for liver cancer by α-fetoprotein-controlled oncolytic adenovirus expression of SOCS3 and IL-24.
|
21835849 |
2011 |
|
Adult Liver Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PEG-PEI/Fe₃O₄ nanomagnetic fluid successfully transfected PEGFP-AFP-hTNFα into HepG2 cells and induced expression of hTNFα gene in the HepG2 cells, thus showing promise as a gene vector for liver cancer gene therapy.
|
21621154 |
2011 |
|
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
α-Fetoprotein (AFP), which is a serological marker of liver cancer, was used as a model analyte to test STA-AQ in an immunoassay.
|
21389603 |
2011 |
|
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we review the transcription factors that regulate AFP in the fetal liver, as well as Zhx2 and Zbtb20, and raise the possibility that the loss of these postnatal repressors may be involved in AFP reactivation in liver cancer.
|
21216289 |
2011 |
|
Adult Liver Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression cassette AFP-HCCS1-WPRE-SV40 was inserted into Ad.SPDD to form Ad.SPDD-HCCS1, enabling us to improve the safety and efficacy of oncolytic-mediated gene therapy for liver cancer.
|
22040050 |
2011 |
|
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The design of Ad.enAFP-E1A-ΔE1B-IL-24 and its potent antitumor effect on liver cancer have not been published previously.
|
22790965 |
2012 |
|
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To achieve liver cancer targeting and to improve the safety of the ZD55 vector (a widely-used E1B55KD gene-deleted oncolytic adenoviral vector (OV), we previously constructed), we designed a novel OV named Ad·AFP·D55 that selectively replicates in hepatocellular carcinoma (HCC) cells by replacing the E1A promoter with the liver-cancer specific α-Fetoprotein (AFP) promoter based on the ZD55 vector.
|
21979578 |
2012 |
|
Adult Liver Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
There were significant differences between the two groups in term of alpha-fetoprotein (α-FP) level (p<0.01), tumor size (p<0.01), TNM stage (p<0.01), recurrence incidence (p<0.01) and family history of liver cancer (p<0.01).
|
23556002 |
2013 |
|
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We coated replication-deficient (Ad5-CMV/NIS) (CMV is cytomegalovirus) and replication-selective (Ad5-E1/AFP-E3/NIS) adenovirus serotype 5 carrying the hNIS gene with poly(amidoamine) dendrimers generation 5 (PAMAM-G5) in order to investigate transduction efficacy and altered tropism of these coated virus particles by (123)I scintigraphy and to evaluate their therapeutic potential for systemic radiovirotherapy in a liver cancer xenograft mouse model.
|
23843567 |
2013 |
|
Adult Liver Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Effects of AFP-activated PI3K/Akt signaling pathway on cell proliferation of liver cancer.
|
24425104 |
2014 |
|
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results suggest that Alpha-fetoprotein may play a regulatory role on angiogenesis and cell invasion during liver cancer development.
|
24587407 |
2014 |
|
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our previous studies indicated that targeted expression of therapeutic BikDD driven by a liver cancer-specific α-fetoprotein promoter/enhancer (eAFP) in the VISA backbone (eAFP-VISA-BikDD) significantly and specifically kills HCC cells in multiple orthotopic animal models.
|
26247632 |
2015 |
|
Adult Liver Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Subgroup analysis among patients with tumor size ≤ 5.0 cm (n=109), patients at Barcelona Clinic Liver Cancer stage 0 or A (n=92), and patients with α-fetoprotein ≤ 20 ng/mL (n=61), the ATAD2-positive groups unfavorably influenced RFS (p=0.008, p=0.009, and p=0.013, respectively).
|
25687855 |
2015 |
|
Adult Liver Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Even in clinical liver cancer samples, the expression of α-fetoprotein and Jagged1 showed significant correlation, and amplification of the copy number of Jagged1 was associated with Jagged1 mRNA expression and poor survival after liver cancer surgical resection.
|
27315779 |
2016 |
|
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Due to the small risk of liver cancer development, screening for liver cancer (especially HCC) is still recommended in HT1 patients using regular measures of α-fetoprotein and imaging.
|
28755188 |
2017 |
|
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Univariate and multivariate analyses revealed the SHI was an independent predictor for overall survival and relapse-free survival, and prognostic for patients with negative α-fetoprotein and Barcelona Clinic Liver Cancer stage 0+A.
|
28769812 |
2017 |
|
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
AFP is an important target in the treatment of liver cancer.
|
28554567 |
2017 |
|
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Best performance was found for CEA in colorectal cancer (area under the curve=0.84, sensitivity=51.7% at 95% specificity vs. benign), CA19-9 in gallbladder/pancreatic cancer (AUC=0.85, sensitivity=60.6%) and AFP in liver cancer (AUC=0.87, sensitivity=68.4%).
|
28011514 |
2017 |
|
Adult Liver Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
HBx drives alpha fetoprotein expression to promote initiation of liver cancer stem cells through activating PI3K/AKT signal pathway.
|
27925189 |
2017 |
|
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
As a proof of concept, α-fetoprotein (AFP) was detected as a target, which is a biomarker of liver cancer.
|
28155925 |
2017 |